Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Simpson

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Annals of Thoracic Surgery Short Reports|April 24, 2026
ProtekDuo in Lung Transplant Candidates: Insights From a Single-Center Study of CasesDomingo J Franco-Palacios, Sharon Raymond-Forde, Kaitlin Olexsey, et al.
Journal of Dermatological Science|June 12, 2021
Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agentsThomas Luger, Masayuki Amagai, Brigitte Dreno, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 14, 2018
Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitisJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
The British Journal of Dermatology|December 11, 2025
Topical Steroid Withdrawal (TSW) Syndrome: Developing Diagnostic Criteria through a Modified Delphi MethodCynhia Hsu, Lily Guo, Derrick Adams, et al.
Advances in Therapy|September 9, 2024
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Advances in Therapy|December 5, 2024
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
The Journal of Dermatological Treatment|August 9, 2021
The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statementDaniel C Butler, Eric Simpson, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|October 11, 2016
Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic DermatitisYuangang Liu, Zhiping Wang, Rachel De La Torre, et al.
The Journal of Investigative Dermatology|August 15, 2025
Improving the quality of atopic dermatitis epidemiological research in the United States- A systematic review of disease definitions and related content in national surveysSarah L Becker, Gina N Bash, Wendy Smith Begolka, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Annals of Thoracic Surgery Short Reports|April 24, 2026
ProtekDuo in Lung Transplant Candidates: Insights From a Single-Center Study of CasesDomingo J Franco-Palacios, Sharon Raymond-Forde, Kaitlin Olexsey, et al.
Journal of Dermatological Science|June 12, 2021
Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agentsThomas Luger, Masayuki Amagai, Brigitte Dreno, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 14, 2018
Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitisJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
The British Journal of Dermatology|December 11, 2025
Topical Steroid Withdrawal (TSW) Syndrome: Developing Diagnostic Criteria through a Modified Delphi MethodCynhia Hsu, Lily Guo, Derrick Adams, et al.
Advances in Therapy|September 9, 2024
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
Advances in Therapy|December 5, 2024
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)Eric Simpson, Pablo Fernández-Peñas, Marjolein de Bruin-Weller, et al.
The Journal of Dermatological Treatment|August 9, 2021
The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statementDaniel C Butler, Eric Simpson, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|October 11, 2016
Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic DermatitisYuangang Liu, Zhiping Wang, Rachel De La Torre, et al.
The Journal of Investigative Dermatology|August 15, 2025
Improving the quality of atopic dermatitis epidemiological research in the United States- A systematic review of disease definitions and related content in national surveysSarah L Becker, Gina N Bash, Wendy Smith Begolka, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Pageof 8